These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26302254)

  • 1. Engineering the AAV capsid to optimize vector-host-interactions.
    Büning H; Huber A; Zhang L; Meumann N; Hacker U
    Curr Opin Pharmacol; 2015 Oct; 24():94-104. PubMed ID: 26302254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectrology of adeno-associated viruses (AAV).
    Skubis-Zegadło J; Stachurska A; Małecki M
    Med Wieku Rozwoj; 2013; 17(3):202-6. PubMed ID: 24296444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
    Kwon I; Schaffer DV
    Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.
    Grimm D; Büning H
    Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the AAV capsid to evade immune responses.
    Barnes C; Scheideler O; Schaffer D
    Curr Opin Biotechnol; 2019 Dec; 60():99-103. PubMed ID: 30807882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

  • 8. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.
    Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H
    Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
    Schön C; Biel M; Michalakis S
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring the AAV vector capsid for gene therapy.
    Vandenberghe LH; Wilson JM; Gao G
    Gene Ther; 2009 Mar; 16(3):311-9. PubMed ID: 19052631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
    Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
    Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV's anatomy: roadmap for optimizing vectors for translational success.
    Mitchell AM; Nicolson SC; Warischalk JK; Samulski RJ
    Curr Gene Ther; 2010 Oct; 10(5):319-340. PubMed ID: 20712583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of AAV vectors to target persistent viral reservoirs.
    Colón-Thillet R; Jerome KR; Stone D
    Virol J; 2021 Apr; 18(1):85. PubMed ID: 33892762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor targeting of adeno-associated virus vectors.
    Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
    Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
    Masat E; Pavani G; Mingozzi F
    Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.
    Muzyczka N; Warrington KH
    Hum Gene Ther; 2005 Apr; 16(4):408-16. PubMed ID: 15871672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody.
    Bartlett JS; Kleinschmidt J; Boucher RC; Samulski RJ
    Nat Biotechnol; 1999 Feb; 17(2):181-6. PubMed ID: 10052356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
    Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
    Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.
    Nicklin SA; Buening H; Dishart KL; de Alwis M; Girod A; Hacker U; Thrasher AJ; Ali RR; Hallek M; Baker AH
    Mol Ther; 2001 Sep; 4(3):174-81. PubMed ID: 11545607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.